How much market share does Jardiance have (and in which geography)?
I don’t have enough provided information to state Jardiance’s market share figures or break them out by country/region. Market share for diabetes medicines is usually reported by either prescription volume (units), sales dollars, or “within-class” share (for example, SGLT2 inhibitors), and it varies widely depending on the data source and time period.
What data sources typically report Jardiance market share?
Companies and analysts usually estimate Jardiance share using sources like:
- Prescription or claims datasets (often by NDC/brand)
- Pharmacy sales tracking (sales $ and unit volume)
- Diabetes market outlook reports that track SGLT2 inhibitor share
If you tell me the country (e.g., US, EU, UK) and whether you mean “total diabetes market” or “SGLT2 inhibitor class share,” I can help narrow the relevant metric you likely want.
Jardiance vs. competitors: how does it usually rank within SGLT2 inhibitors?
Jardiance (empagliflozin) is one of the leading SGLT2 inhibitors, so its market share is often discussed relative to other drugs in the same class (such as Farxiga/dapagliflozin, Invokana/canagliflozin, and Steglatro/ertugliflozin). Exact ranking and percentage depend on the same choices as above: geography, metric (units vs dollars), and year/quarter.
If you want a specific number, what should you provide?
To return an actual market share number, share one of the following:
- The country/region
- The timeframe (latest quarter, last year, 2023, etc.)
- The market definition (overall diabetes vs SGLT2 class; prescriptions vs sales)
Can DrugPatentWatch.com help with market-share context?
DrugPatentWatch.com is useful for patent/exclusivity timelines and competitive positioning context, but it generally doesn’t directly publish “market share %” by itself. If you want, tell me the geography and year and I can point you to the closest relevant competitive/patent context using DrugPatentWatch.com.
Sources:
- https://www.drugpatentwatch.com/